Editing Biogen (section)

== Products ==
{|class="wikitable sortable"
|-
!Therapy!!Indication (In United States unless otherwise noted)!!Year Approved (US)!!Year Approved (EU)!!Additional Information
|-
|LEQEMBI™ [([[lecanemab-irmb]])]
|Indicated for patients with mild cognitive impairment or mild dementia stages of Alzheimer's disease.
|2023
|(pending)
|Biogen and Japanese [[Eisai (company)|Eisai]] are collaborators in the development and commercialization of LEQEMBI.<ref>{{Cite web |title=Companies in Alzheimer's race after US nod for Eisai/Biogen drug |url=https://www.reuters.com/business/healthcare-pharmaceuticals/companies-alzheimers-race-after-us-nod-eisaibiogen-drug-2023-07-07/ |website=Reuters}}</ref>
|-
|ADUHELM™ [([[aducanumab]]) Human Immunoglobulin Gamma 1 (IgG1) [[monoclonal antibody]]]||Indicated for all stages of Alzheimer's disease,  including patients with confirmed presence of amyloid pathology and mild cognitive impairment or mild dementia.||2021 ||(pending)|| U.S. FDA accelerated approval.
Biogen and Japanese [[Eisai (company)|Eisai]] are collaborators in the development and commercialization of ADUHELM.<ref>{{cite web
   |url        = https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf
   |title      = ADUHELMTM (aducanumab-avwa) injection, for intravenous use, prescribing Information
   |publisher  = FDA.gov
   |access-date=2021-06-09
}}</ref>
|-
|ALPROLIX™ [Coagulation [[Factor IX]] (Recombinant), Fc Fusion Protein]||Control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with [[hemophilia B]]||2021 ||1993||Also approved in Canada and Australia.
Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ALPROLIX.<ref>{{cite web
   |url        = http://www.fool.com/investing/general/2014/04/07/does-biogen-idec-inc-have-a-new-blockbuster-hemoph.aspx
   |title      = Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?
   |date = 7 April 2014
 |publisher  = The Motley Fool
   |access-date=2014-07-04
}}</ref>
|-
|[[Avonex|AVONEX®]] ([[interferon beta-1a]])||Relapsing forms of [[multiple sclerosis]]||1996 ||1997 ||Includes the AVONEX PEN auto-injector and the AVOSTARTGRIP titration kit approved in the U.S. in 2012.<ref>{{cite web
   |url        = http://www.nationalmssociety.org/Treating-MS/Medications/Avonex
   |title      = Avonex
   |publisher  = National MS Society
   }}</ref>
|-
|ELOCTATE™ [Antihemophilic Factor (Recombinant), Fc Fusion Protein]||Control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with [[hemophilia A]]||2014 ||1999||Biogen and Swedish Orphan Biovitrum (Sobi) are collaborators in the development and commercialization of ELOCTATE.<ref>{{cite web
   |url        = http://www.thepharmaletter.com/article/biogen-idec-s-eloctate-gains-fda-approval
   |title      = Biogen Idec's Eloctate gains FDA approval
   |publisher  = The Pharma Letter
   |access-date=2014-09-06
}}</ref>
|-
|FAMPYRA (prolonged-release [[4-Aminopyridine|fampridine]] tablets)||[[Multiple sclerosis]] (Walking ability)||2010 ||2011 ||Marketed by Biogen in markets outside of the United States.

Commercialized in the United States as AMPYRA (dalfampridine) Extended Release Tablets, by [[Acorda Therapeutics]].<ref>{{cite web
   |url        = http://www.mstrust.org.uk/atoz/fampridine.jsp
   |title      = Fampridine (Fampyra)
   |publisher  = MS Trust
   }}</ref>
|-
|FUMADERM (fumaric acid esters)||[[Psoriasis]] German use || ||1994 (Germany only) ||Approved in Germany.

Acquired in acquisition of Fumapharm AG in 2006.<ref>{{cite web
   |url        = http://www.firstwordpharma.com/node/149468
   |title      = Biogen Idec enters deal to acquire Fumapharm
   |publisher  = First Word Pharma
   |access-date=2006-05-31
}}</ref>
|-
|GAZYVA ([[obinutuzumab]])||[[Chronic lymphocytic leukemia]]||2013 ||2014 ||The first medicine approved with the FDA's Breakthrough Therapy Designation and is also currently in Phase 3 trials for NHL and diffuse large B-cell lymphoma.

Currently commercialized in the United States by Genentech, a wholly owned subsidiary of Roche.<ref>{{cite web|title=FDA approves Gazyva for chronic lymphocytic leukemia|url=https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm373209.htm|archive-url=https://web.archive.org/web/20131102162817/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm373209.htm|url-status=dead|archive-date=November 2, 2013|access-date=2013-01-11|publisher=FDA}}</ref>
|-
|IMRALDI ([[adalimumab]])
|Immunosuppressive drug to treat autoimmune disorders such as [[inflammatory bowel disease]]
|2019
|2018
|Biosimilar of [[AbbVie]]'s Humira.<ref>{{Cite web|title=FDA Approves Adalimumab Biosimilar, Samsung Bioepis' Hadlima|url=https://www.centerforbiosimilars.com/view/fda-approves-adalimumab-biosimilar-samsung-bioepis-hadlima|access-date=2021-06-07|website=The Center For Biosimilars|date=24 July 2019 }}</ref><ref>{{Cite web|title=IMRALDI™, Biogen's Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union {{!}} Biogen|url=http://media.biogen.com/news-releases/news-release-details/imralditm-biogens-adalimumab-biosimilar-referencing-humirar|access-date=2021-06-07|website=media.biogen.com|language=en}}</ref>
|-
|SPINRAZA ([[nusinersen]])
|[[Spinal muscular atrophy]] (SMA)
|2016
|2017
|The first drug approved for the treatment of [[spinal muscular atrophy]], developed in collaboration with [[Ionis Pharmaceuticals]].<ref>{{cite journal|last1=Wadman|first1=Meredith|title=Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease|journal=Science|date=23 December 2016|url=http://www.sciencemag.org/news/2016/12/novel-drug-rescues-babies-fatal-neurodegenerative-disease|doi=10.1126/science.aal0476|url-access=subscription}}</ref><ref>{{Cite news|url=https://www.wsj.com/articles/surprise-drug-approval-is-holiday-gift-for-biogen-1482856447|title=Surprise Drug Approval Is Holiday Gift for Biogen|last=Grant|first=Charley|date=2016-12-27|newspaper=Wall Street Journal|issn=0099-9660|access-date=2016-12-27}}</ref>
|-
|[[Plegridy|PLEGRIDY]] (peginterferon beta-1a)||Relapsing forms of multiple sclerosis||2014<ref>{{cite web
   |url        = https://www.reuters.com/article/2014/08/15/ma-biogen-idec-idUSnBw155610a+100+BSW20140815
   |title        = Biogen Idec's PLEGRIDY(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
   |publisher        = Reuters
   |access-date        = 2017-06-30
   |archive-date        = 2014-09-16
   |archive-url        = https://archive.today/20140916191335/http://www.reuters.com/article/2014/08/15/ma-biogen-idec-idUSnBw155610a+100+BSW20140815
   |url-status        = dead
   }}</ref> ||2014<ref>{{cite web
   |url        = http://www.thepharmaletter.com/article/biogen-idec-s-plegridy-approved-in-europe-for-relapsing-remitting-multiple-sclerosis
   |title      = Biogen Idec's Plegridy approved in Europe for relapsing-remitting multiple sclerosis
   |publisher  = The Pharma Letter
   }}</ref> ||
|-
|RITUXAN ([[rituximab]])||[[Non-Hodgkin lymphoma]] (NHL)

Anti-TNF Refractory Rheumatoid Arthritis

ANCA-Associated Vasculitis

[[Chronic lymphocytic leukemia]]
||1997<ref>{{cite web
   |url        = http://www.cancer.gov/cancertopics/druginfo/fda-rituximab
   |title      = FDA Approval for Rituximab
   |publisher  = National Cancer Institute
   }}</ref>

2006<ref>{{cite news
   |url        = https://www.reuters.com/article/biogen-roche-idUSN2110240020101021
   |title        = UPDATE 1-Roche, Biogen end dispute over Rituxan follow-ons
   |date = 21 October 2010
 |work        = Reuters
   |access-date        = 2010-10-21
   |archive-date        = 2014-07-27
   |archive-url        = https://web.archive.org/web/20140727222723/http://www.reuters.com/article/2010/10/21/biogen-roche-idUSN2110240020101021
   |url-status        = live
   }}</ref>

2011<ref>{{cite web|title=FDA approves Rituxan to treat two rare disorders|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm|archive-url=https://web.archive.org/web/20110420004402/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm251946.htm|url-status=dead|archive-date=April 20, 2011|access-date=2011-04-19|publisher=FDA}}</ref>
||1998 (as MabThera) ||The first monoclonal antibody for cancer developed by IDEC, prior to merging with Biogen.

Currently commercialized by Roche and its subsidiary, Genentech.
|-
|TECFIDERA (dimethyl fumarate)||Relapsing forms of [[multiple sclerosis]]||2013<ref>{{cite web
   |url        = http://www.thepharmaletter.com/article/cell-therapeutics-buys-zevalin-from-biogen-idec-for-10m-with-up-to-20m-extra-plus-milestones
   |title      = Cell Therapeutics buys Zevalin from Biogen Idec for $10M, with up to $20M extra plus milestones
   |publisher  = The Pharma Letter
   |access-date=2007-09-03
}}</ref> ||2014<ref>{{cite web
   |url        = http://www.nationalmssociety.org/Treating-MS/Medications/Tecfidera%E2%84%A2
   |title      = Tecifedra
   |publisher  = National MS Society
   }}</ref> ||
|-
|TYSABRI ([[natalizumab]])||Relapsing-remitting [[multiple sclerosis]]||2004 Re-introduced in 2006 ||2006 ||Full rights purchased from partner Elan in 2013.<ref>{{cite web
   |url        = http://www.nationalmssociety.org/Treating-MS/Medications/Tysabri-%C2%AE
   |title      = Tysabri
   |publisher  = National MS Society
   }}</ref>
|-
|}